Abstracts tagged "Personalized Medicine and rheumatoid arthritis (RA)"

Abstract Number: 1610 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Changes Observed in Rheumatoid Arthritis Joint Tissue Are Detectable in CD4+ Naive T Cells from Peripheral Blood
Calliope Holingue¹, Brooke Rhead¹, Michael Cole¹, Xiaorong Shao¹, Hong L. Quach¹, Diana Quach¹, Elizabeth Sinclair², Jonathan D. Graf³, Thomas M. Link⁴, Ruby Harrison⁵, Vladimir Chernitskiy⁶, Wei Wang⁷, Gary S. Firestein⁸, Lisa F. Barcellos¹ and Lindsey A. Criswell⁵, ¹Genetic Epidemiology and Genomics Laboratory, University of California, Berkeley, Berkeley, CA, ²Division of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, ³Div Of Rheumatology, Division of Rheumatology, UCSF, San Francisco, CA, ⁴Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ⁵Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, ⁸Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA
Background/Purpose: Aberrant DNA methylation patterns have previously been associated with rheumatoid arthritis (RA) [MIM 180300]. Our study aimed to determine whether differentially methylated CpGs in…
Abstract Number: 2520 • 2014 ACR/ARHP Annual Meeting
Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
Michael D. Wiese¹, Ashley Hopkins², Llew Spargo³, Leah McWilliams³, Catherine O'Doherty², Leslie G. Cleland³ and Susanna Proudman⁴, ¹Division of Health Sciences, School of Pharmacy, University of South Australia, Adelaide, Australia, ²School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose . Leflunomide is a disease modifying anti-rheumatic drug that is used in the treatment of rheumatoid arthritis (RA). Leflunomide is converted to teriflunomide by the…
Abstract Number: 1452 • 2013 ACR/ARHP Annual Meeting
An Early Economic Evaluation Of Personalized Treatment With Rituximab By Prediction Of Effectiveness Using The Interferon Type I Signature In Rheumatoid Arthritis
Sandhya C. Nair¹, P.M.J. Welsing², Saskia Vosslamber³, A.E. Voskuyl⁴, M. T. Nurmohamed⁵, J.W.J. Bijlsma², Floris Lafeber⁶ and Cornelis L. Verweij⁷, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Pathology, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ⁶Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁷Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Tailoring therapy to individual patients, for instance by predicting its effectiveness has become increasingly important especially with chronic use of expensive biological DMARDs.To evaluate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].